ZA201800826B - Substituted oxopyridine derivatives - Google Patents

Substituted oxopyridine derivatives

Info

Publication number
ZA201800826B
ZA201800826B ZA2018/00826A ZA201800826A ZA201800826B ZA 201800826 B ZA201800826 B ZA 201800826B ZA 2018/00826 A ZA2018/00826 A ZA 2018/00826A ZA 201800826 A ZA201800826 A ZA 201800826A ZA 201800826 B ZA201800826 B ZA 201800826B
Authority
ZA
South Africa
Prior art keywords
oxopyridine derivatives
substituted oxopyridine
substituted
derivatives
oxopyridine
Prior art date
Application number
ZA2018/00826A
Other languages
English (en)
Inventor
Nunez Eloisa Jimenez
Jens Ackerstaff
Susanne Röhrig
Alexander Hillisch
Katharina Meier
Stefan Heitmeier
Adrian Tersteegen
Jan Stampfuss
Daniel Meibom
Dieter Lang
Ellerbrock Pascal
Original Assignee
Muellerstrasse 178 Berlin 13353 Germany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Muellerstrasse 178 Berlin 13353 Germany filed Critical Muellerstrasse 178 Berlin 13353 Germany
Publication of ZA201800826B publication Critical patent/ZA201800826B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
ZA2018/00826A 2015-07-09 2018-02-08 Substituted oxopyridine derivatives ZA201800826B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15176099 2015-07-09
EP16157350 2016-02-25
PCT/EP2016/065787 WO2017005725A1 (en) 2015-07-09 2016-07-05 Substituted oxopyridine derivatives

Publications (1)

Publication Number Publication Date
ZA201800826B true ZA201800826B (en) 2021-08-25

Family

ID=56345141

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2018/00826A ZA201800826B (en) 2015-07-09 2018-02-08 Substituted oxopyridine derivatives

Country Status (39)

Country Link
US (4) US10421742B2 (enExample)
EP (1) EP3319956B1 (enExample)
JP (1) JP6871180B2 (enExample)
KR (1) KR102596164B1 (enExample)
CN (2) CN108026072B (enExample)
AU (1) AU2016289746B2 (enExample)
CA (1) CA2990901C (enExample)
CL (1) CL2018000039A1 (enExample)
CO (1) CO2018000113A2 (enExample)
CR (1) CR20180017A (enExample)
CU (1) CU24512B1 (enExample)
CY (1) CY1123996T1 (enExample)
DK (1) DK3319956T3 (enExample)
DO (1) DOP2018000004A (enExample)
EA (1) EA036208B1 (enExample)
EC (1) ECSP18001308A (enExample)
ES (1) ES2856554T3 (enExample)
GE (1) GEP20197046B (enExample)
HR (1) HRP20210459T1 (enExample)
HU (1) HUE053552T2 (enExample)
IL (1) IL256556B (enExample)
JO (1) JO3703B1 (enExample)
LT (1) LT3319956T (enExample)
MA (1) MA42376B1 (enExample)
MX (1) MX377903B (enExample)
MY (1) MY196640A (enExample)
NI (1) NI201800001A (enExample)
PE (1) PE20180538A1 (enExample)
PH (1) PH12018500057A1 (enExample)
PL (1) PL3319956T3 (enExample)
RS (1) RS61584B1 (enExample)
SI (1) SI3319956T1 (enExample)
SV (1) SV2018005610A (enExample)
TN (1) TN2018000011A1 (enExample)
TW (1) TWI717367B (enExample)
UA (1) UA122341C2 (enExample)
UY (1) UY36780A (enExample)
WO (1) WO2017005725A1 (enExample)
ZA (1) ZA201800826B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CA2979937A1 (en) * 2015-03-19 2016-09-22 Bayer Pharma Aktiengesellschaft Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
ES2920449T3 (es) * 2018-03-15 2022-08-04 Bayer Ag Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida
PE20210165A1 (es) 2018-04-10 2021-01-26 Bayer Pharma AG Un derivado de oxopiridina sustituido
EP3822264A4 (en) 2018-07-02 2021-11-10 Jiangsu Hengrui Medicine Co., Ltd. CRYSTALLINE FORMS OF AN OXYPYRIDINE AMIDE DERIVATIVE AND THEIR PREPARATION PROCESS
AR115870A1 (es) 2018-07-31 2021-03-10 Sumitomo Chemical Co MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ
CA3123324A1 (en) * 2018-12-17 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
CN113474348A (zh) 2018-12-21 2021-10-01 拜耳公司 取代的氧代吡啶衍生物
WO2020127508A1 (en) 2018-12-21 2020-06-25 Bayer Aktiengesellschaft Substituted oxopyridine derivatives
EP4036087A4 (en) * 2019-09-27 2023-09-20 Shenzhen Salubris Pharmaceuticals Co. Ltd Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
CN116348109B (zh) 2020-09-17 2025-01-21 浙江海正药业股份有限公司 哌嗪类衍生物及其制备方法和用途
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
EP4304561A1 (en) * 2021-03-09 2024-01-17 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
JP2024508971A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト (4s)-24-クロロ-4-エチル-73-フルオロ-35-メトキシ-32,5-ジオキソ-14-(トリフルオロメチル)-32h-6-アザ-3(4,1)-ピリジナ-1(1)-[1,2,3]トリアゾラ-2(1,2),7(1)-5 ジベンゼナヘプタファン-74-カルボキサミドの結晶形態
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
CN113666826B (zh) * 2021-07-30 2024-03-26 五邑大学 一种芳基或杂芳基甲氧基化反应的方法
CN116199672A (zh) * 2021-11-30 2023-06-02 成都泰和伟业生物科技有限公司 一种嘧啶酰胺类衍生物及其制备方法和用途
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116262735B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262740A (zh) * 2022-11-18 2023-06-16 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
CN116262734B (zh) * 2022-11-18 2025-05-13 成都施贝康生物医药科技有限公司 氧代吡啶类化合物及其制备方法和用途
CN116082303B (zh) 2022-12-21 2025-02-25 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116262736B (zh) * 2022-12-26 2025-05-13 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其制备方法和用途
KR20250164210A (ko) 2023-03-31 2025-11-24 바이엘 악티엔게젤샤프트 (4s)-24-클로로-4-에틸-73-플루오로-35-메톡시-32,5-디옥소-14-(트리플루오로메틸)-32h-6-아자-3(4,1)-피리디나-1(1)-[1,2,3]트리아졸라-2(1,2),7(1)-디벤제나헵타판-74-카르복스아미드를포함하는 제약 투여 형태
WO2024251276A1 (zh) * 2023-06-09 2024-12-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体和应用
CN116751136B (zh) * 2023-06-21 2025-08-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用
CN116621742B (zh) * 2023-06-09 2025-05-06 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116621728B (zh) * 2023-06-09 2025-07-29 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116874387B (zh) * 2023-06-21 2025-08-26 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN116730861A (zh) * 2023-06-21 2023-09-12 成都施贝康生物医药科技有限公司 氧代吡啶类化合物的新型制备方法及关键中间体
CN117164566B (zh) * 2023-09-07 2025-06-06 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117164564B (zh) * 2023-09-07 2025-07-08 成都施贝康生物医药科技有限公司 氧代哒嗪类化合物及其制备方法和用途
CN117164565B (zh) * 2023-09-07 2025-05-27 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164563B (zh) * 2023-09-07 2025-06-10 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN117164561A (zh) * 2023-09-07 2023-12-05 成都施贝康生物医药科技有限公司 一种氧代嘧啶类化合物及其制备方法和用途
CN117164562B (zh) * 2023-09-07 2025-06-13 成都施贝康生物医药科技有限公司 一种氧代哒嗪类化合物及其制备方法和用途
CN117186073B (zh) * 2023-09-08 2025-06-06 成都施贝康生物医药科技有限公司 氧代嘧啶类化合物及其制备方法和用途
CN118894814B (zh) * 2024-07-15 2025-09-12 上海康鹏科技股份有限公司 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1,2,3-三唑的制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
HUP0400651A2 (hu) 2000-11-07 2004-06-28 Bristol-Myers Squibb Company Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
EP1526131A1 (en) 2003-10-22 2005-04-27 Graffinity Pharmaceuticals Aktiengesellschaft Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2016072B1 (en) 2006-05-05 2014-07-16 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2013056034A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
JP6137193B2 (ja) 2011-12-21 2017-05-31 小野薬品工業株式会社 第XIa因子阻害剤としての新規ピリジノンおよびピリミジノン誘導体
CN104507924B (zh) * 2012-08-03 2018-01-23 百时美施贵宝公司 二氢吡啶酮p1作为凝血因子xia抑制剂
EP2968207A4 (en) 2013-03-14 2016-09-28 Chdi Foundation Inc HISTON DEACETYLASE INHIBITORS AND COMPOSITIONS
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015011087A1 (de) 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
CA2928867A1 (en) 2013-10-30 2015-05-07 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
UY35971A (es) 2014-01-31 2015-07-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Macrociclos con grupos p2? aromáticos como inhibidores del factor xia
WO2015120777A1 (zh) * 2014-02-14 2015-08-20 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046159A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
EP3197872B1 (de) 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen
CA2961981A1 (en) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
ES2694189T3 (es) * 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017023992A1 (en) * 2015-08-05 2017-02-09 Bristol-Myers Squibb Company Novel substituted glycine derived fxia inhibitors

Also Published As

Publication number Publication date
CO2018000113A2 (es) 2018-06-12
UY36780A (es) 2017-01-31
JO3703B1 (ar) 2021-01-31
ECSP18001308A (es) 2018-03-31
US20250282748A1 (en) 2025-09-11
US20230024752A1 (en) 2023-01-26
CL2018000039A1 (es) 2018-07-13
HRP20210459T1 (hr) 2021-05-14
US11180471B2 (en) 2021-11-23
US20190367478A1 (en) 2019-12-05
MA42376B1 (fr) 2021-04-30
MY196640A (en) 2023-04-25
IL256556A (en) 2018-02-28
EA201890111A1 (ru) 2018-06-29
MX2018000076A (es) 2018-02-26
HK1255045A1 (zh) 2019-08-02
JP6871180B2 (ja) 2021-05-12
US10421742B2 (en) 2019-09-24
JP2018519323A (ja) 2018-07-19
HUE053552T2 (hu) 2021-07-28
TW201706261A (zh) 2017-02-16
AU2016289746B2 (en) 2020-08-20
KR102596164B1 (ko) 2023-11-01
GEP20197046B (en) 2019-12-10
EA036208B1 (ru) 2020-10-14
US20180194745A1 (en) 2018-07-12
TN2018000011A1 (en) 2019-07-08
EP3319956B1 (en) 2021-01-06
DOP2018000004A (es) 2018-01-31
CN113292539B (zh) 2023-12-22
RS61584B1 (sr) 2021-04-29
CR20180017A (es) 2018-03-07
CN108026072B (zh) 2021-08-17
CN108026072A (zh) 2018-05-11
MX377903B (es) 2025-03-10
NZ739109A (en) 2024-09-27
PE20180538A1 (es) 2018-03-20
PH12018500057A1 (en) 2018-07-09
TWI717367B (zh) 2021-02-01
PL3319956T3 (pl) 2021-07-05
CU24512B1 (es) 2021-05-12
IL256556B (en) 2021-02-28
SV2018005610A (es) 2018-04-27
LT3319956T (lt) 2021-02-10
CA2990901A1 (en) 2017-01-12
ES2856554T3 (es) 2021-09-27
SI3319956T1 (sl) 2021-02-26
BR112018000209A2 (pt) 2018-09-04
NI201800001A (es) 2018-10-19
CY1123996T1 (el) 2022-07-22
CN113292539A (zh) 2021-08-24
CA2990901C (en) 2024-11-12
EP3319956A1 (en) 2018-05-16
MA42376A (fr) 2018-05-16
WO2017005725A1 (en) 2017-01-12
UA122341C2 (uk) 2020-10-26
AU2016289746A1 (en) 2018-01-25
DK3319956T3 (da) 2021-03-29
KR20180026761A (ko) 2018-03-13
CU20180001A7 (es) 2018-06-05

Similar Documents

Publication Publication Date Title
ZA201800826B (en) Substituted oxopyridine derivatives
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL253381B (en) History of h9–pyrrolo–dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3418273T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
IL248629A0 (en) Substances containing diheteroaryl conjugated to cycloalkyl and their uses
AU361999S (en) Ballustrade
PL3097076T3 (pl) Nowe pochodne CYP-eikozanoidowe
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
ZA201802194B (en) Aminoazole derivative
PT3319956T (pt) Derivados de oxopiridina substituída
AU5511P (en) PTK647 Epichloe coenophiala
AU366552S (en) Nutblock
AU367131S (en) USB-charger
AU365008S (en) Playsuit
AU2015165V (en) PWBC12 Chamelaucium uncinatum
AU362754S (en) Playsuit
AU2015211V (en) SGIBL01-0 Scabiosa columbaria
AU2015212V (en) SGIPU2-0 Scabiosa columbaria
AU364191S (en) Tallboy
AU2015003V (en) PencilGL Guichenotia macrantha